Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate, ciltacabtagene autoleucel, or cilta-cel, is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, and a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.

Period	PE Ratio
2019-12-31	N/A
2020-12-31	-11.54
2021-12-31	-10.78
2022-12-31	-21.09
2023-12-31	-20.09
2024-12-31	-30.76

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LEGN	$29.53	+0.54%	1.57M
3
4
5

Legend Biotech Corporation (LEGN) PE Ratio

PE Ratio Data

Get Legend Biotech Corporation Data in Excel

More LEGN Financial Data